In patients treated with docetaxel at # mg/m# as single agent who have serum transaminase levels (ALT and/or AST) greater than # times the ULN concurrent with serum alkaline phosphatase levels greater than # times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia
Pri bolnikih, zdravljenih s # mg docetaksela/m# v monoterapiji, ki imajo serumski transaminazi (ALT, AST ali obe) zvišani nad #, #-kratno ULN in hkrati zvišano serumsko alkalno fosfatazo nad #, #-kratno ULN, obstaja večja nevarnost hudih neželenih učinkov, kot so smrti zaradi zastrupitve, vključno s sepso in gastrointestinalno krvavitvijo, ki sta lahko usodni, febrilne nevtropenije, okužb, trombocitopenije, stomatitisa in astenijeEMEA0.3 EMEA0.3